Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dubermatinib,Decitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study aims to determine the safety and maximum tolerated dose of dubermatinib in combination with decitabine and evaluate the composite complete response rate.
Brand Name : TP-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 23, 2020
Lead Product(s) : Dubermatinib,Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?